Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
“If I knew then what I know now.” Multiple myeloma therapy can be high-risk. How often have I said that to myself over the years since my hematopoietic stem cell transplantation (ASCT aka stem cell transplant) in December of 1995. While HSCT therapy has improved since I had mine, this therapy is still aggressive, toxic therapy.
Improved but still does NOT increase your overall survival (OS). Don’t take my word for it, ask your oncologist.
I should know. I live with
all as a result of my HSCT. And all of these side effects occurred months or years after my ASCT.
I believe that it is critical to learn as much as you can about the different types of HSCTs (allo, auto, and umbilical cord blood) in order to better understand the risks and rewards of this procedure. Knowledge is power as they say.
Please understand that there are a number of evidence-based, non-toxic therapies to either reduce or eliminate many of the side-effects documented below. The sooner you learn about and implement integrative therapies the sooner you will treat possible long-term and late stage side effects of high dose chemotherapy.
I am both a multiple myeloma survivor and MM cancer coach. To learn more about these therapies, scroll down the page, post a question or comment and I will reply ASAP.
“However, hematopoietic stem cell transplantation (HSCT) survivors are at risk of developing long-term complications, such as endocrinopathies, musculoskeletal disorders, cardiopulmonary compromise and subsequent malignancies.
These complications have a direct impact on the morbidity and mortality experienced by HSCT survivors.
“The prevalence of autologous and allogeneic hematopoietic cell transplantation (HCT) survivors continues to increase. Among patients whose disease remains in remission for the first 2-5 years after transplantation, it is estimated approximately 80-90% will be alive over the subsequent 10-years.
However, their relative mortality rates continue to remain higher than their general population peers with late complications contributing to significant long-term morbidity and mortality.
Late effects in HCT survivors include:
A patient-centric and multidisciplinary approach to HCT survivorship care with collaborative and coordinated care from transplant centers and community healthcare providers is necessary to ensure their long-term health. Lifelong followup of HCT survivors is recommended, with established guidelines serving as the template for providing screening and preventive care based on patient-specific exposures. This review discussed common late complications, models for care delivery, and gaps and priorities for future research in the field of HCT survivorship…